Kemwell and Boehringer set to finish biologics plant in India

Kemwell and Boehringer set to finish biologics plant in India

Kemwell is set to complete a new biologics manufacturing facility in Bangalore, India, following its long-term partnership with Boehringer Ingelheim.

The firms teamed up to build the plant – a mini version of Boehringer’s German bio facility – three years ago, with plans for a mutually beneficial partnership afterwards.

Speaking to in-PharmaTechnologist and Outsourcing-Pharma at this year’s Interphex in New York, Kemwell’s director of corporate development Christian Ahlmark said the firm would support clinical and small scale commercial production through the plant, whilst Boehringer would take large-scale clients.

The plant – which will produce monoclonal and peptides for small scale projects, amongst other things – will be completed in Q3 this year.

Ahlmark also spoke to us about Kemwell’s recently opened cGMP (current good manufacturing practice) oral liquid dose plant in India.

“That is serving a global market, where previously our Indian operations were solely for India, and it’s capable of 300m bottles of oral liquid product per year,” he said.

Related News

India launches 'similar biologics' guidelines at BIO2012

India launches 'similar biologics' guidelines at BIO2012

SPIC: wants standard excise tax for pharmaceutical CMOs

All Indian pharmaceutical CMOs must pay the excise duty, says SPIC

Theorem and Gallus partnership: helps emerging market drug producers

Theorem and Gallus team up to help drugsmakers in emerging markets go State side

Boehringer will make E.coli amongst other HP clinical materials for Molecular Partners

Boehringer set to make E.coli for clinical trials

NPPA to inspect Indian plants as part of pricing role

NPPA to inspect Indian drug plants as part of pricing role

Kemwell to make pharmaceutical for Mercury in Uppsala

Contract wins show Sweden is emerging CMO hub says Kemwell

Kemwell plant passes inspection

Kemwell plant passes US FDA inspection

Marshmallow toasting opportunities en route to Interphex in 2010

Lack of Lava-Proof Planes Wont Stop Us Going to Interphex

Dedicated Analytical Expansion Could Target New Clients, says Kemwell

Dedicated Analytical Expansion Could Target New Clients, says Kemwell

Kemwell spoke to Outsourcing-Pharma.com at Interphex, New York

Kemwell Talks Expansion and Approvals in India and the US

Kemwell buys Cirrus

Kemwell Acquires US Delivery Development Firm

Kemwell's new Bangalore facility to service first Western biopharma

Kemwell opens doors to West with first mAb deal from Indian plant

Kemwell inks first deal at new Indian biomanufacturing plant

Kemwell inks first deal at new Indian biomanufacturing plant

Kemwell CEO discusses green manufacturing

Kemwell CEO says environmental efforts are worth the cost

Kemwell adds cGMP pilot plant to expand capabilities in India

Granules and Ajinomoto OmniChem to open Indian API facility

Boehringer buying Amgen site to expand biologics CMO biz

Boehringer buying Amgen site to expand biologics CMO biz

Boehringer Ingelheim boosts fill/finish capacity

Elan announces therapeutics deal with Boehringer

PPS admits falsifying record for a 2007 trial of Boehringer’s ‘female viagra’